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Fibrodysplasia ossificans progressiva (FOP) is a rare and devastating genetic disease, in which soft connective tissue is
converted into heterotopic bone through an endochondral ossification process. Patients succumb early as they gradually
become trapped in a second skeleton of heterotopic bone. Although the underlying genetic defect is long known, the
inherent complexity of the disease has hindered the discovery of effective preventions and treatments. New developments
in the gene therapy field have motivated its consideration as an attractive therapeutic option for FOP. However, the
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immune system’s role in FOP activation and the as-yet unknown primary causative cell, are crucial issues which must be
taken into account in the therapy design. While gene therapy offers a potential therapeutic solution, more knowledge
about FOP is needed to enable its optimal and safe application.
Keywords: fibrodysplasia ossificans progressiva, gene therapy, heterotopic ossification, ALK2 mutation, RNA

FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP; MIM no.
135100) is a rare genetic disease affecting soft connective
tissues. The prevalence is reported to be 1 in 1.3 million -2
million.1 FOP is characterized by muscles, tendons, and
ligaments that turn into bone through an endochondral
ossification process.2 Bone formation typically transpires
through so-called flare-ups (Fig. 1), a local inflammatory
response which subsequently triggers local chondrogenesis and osteogenesis.3 In addition to the flare-ups, there is
also a level of basal chronic heterotopic ossification (HO)
present in FOP patients.4 During life, FOP follows a progressive pattern first affecting the axial skeleton and later
the appendicular skeleton, although it varies greatly between patients. Eventually, this highly complex disease
leads to devastating contractures and severe disability and
causes premature death in FOP patients due to thoracic
insufficiency syndrome, trauma, or sepsis.5
The underlying cause of FOP is a heterozygous, usually
de novo, R206H gain-of-function mutation in the ubiquitously expressed bone morphogenetic protein (BMP) type

Figure 1. A flare-up with swelling of the back of a young girl diagnosed
with FOP. Image is reproduced with the written consent of the patient and
her parents. FOP, fibrodysplasia ossificans progressiva.

I receptor activin receptor-like kinase 2 (ALK2) (Fig. 2).
This mutation alters the properties of the receptor by
converting it to a form that is both mildly constitutively
active at the basal state and hyperactive to BMP signaling
in the activated state as evidenced by the phosphorylation
of the downstream SMAD1/5/8 effector proteins.6,7 Also,
the mutation renders the ALK2 receptor aberrantly responsive to Activin A, which induces phosphorylation of
SMAD 1/5/8, leading to bone formation where it normally
would not occur.8
It is still unclear what other factors contribute to the
unpredictable and episodic activity of the disease, although an important role is attributed to the immune system.9–12 The R206H (c.617G>A) mutation can be found in
more than 95% of the classic form of FOP patients. Currently, at least 13 other mutations have been found in the
glycine-serine rich or kinase domain of ALK2 that cause
FOP, which appear to lead to different phenotypes than
the ‘‘classic’’ FOP. Nonetheless, they are all heterozygous missense mutations, which enhance receptor signaling (Fig. 1).13
Presently, it is not known when the disease may become active, although (minor) trauma is one of the most
predictive triggering factors. Several drugs are currently
being investigated in clinical trials and represent different molecular strategies.14 These include blocking
antibodies that stop Activin A from triggering the mutant
ALK2 receptor (REGN2477),15,16 ALK2 kinase inhibitors
(AZD0530; IPN60130),17,18 mTOR inhibitors which
modulate the inflammatory response to tissue injury and
aim to affect the early hypoxic stages involved in chondrogenesis (rapamycin)19 and retinoic acid receptor
gamma agonists, which block the chondrogenic signaling
required for endochondral bone formation (palovarotene).20,21 All of these experimental approaches have
been shown to be effective in FOP mouse models.15,18,22,23
Given the nature of this mutation and the importance of
the ALK2 receptor in homeostasis and development of the
skeletal system, pharmaceutical interference with the receptor can be expected to cause numerous potential side
effects. Demonstrating the effect of intervention with
these drugs in clinical studies has already appeared to be
more difficult than initially expected in terms of acceptable risks, expected benefits, and lack of comprehensive
understanding of the natural history of the disease. Clinical
trials are currently being conducted to further evaluate the
safety and efficacy of the aforementioned drugs. However,
at the time of this article, no efficacy and safety data have
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Figure 2. Overview of FOP mutations in the exons of the different domains of the ACVR1 gene. Figure 2 was created with biorender.com. EC, extracellular; GS,
glycine-serine rich; KD, kinase domain; TM, transmembrane; UTR, untranslated region.

yet been published and, with the exception of approval of
palovarotene in Canada, no drugs have been approved by
regulatory authorities elsewhere.
The complexity of finding safe and effective treatments specific to the known genetic cause is why gene
therapy is being explored as a new treatment option in
FOP. For many monogenic diseases, the gene therapy
horizon is being intensively explored as it offers attractive possibilities which seem tangible in the near future;
this has motivated the investigation and investment in the
gene therapy approach. Considering the therapeutic benefits of commercialized gene therapy on several monogenic diseases such as lipoprotein lipase deficiency,24
inherited retinal dystrophy,25 and spinal muscular atrophy,26 it is plausible that current gene therapy options
could be beneficial for the treatment of FOP caused by a
monogenic gain-of-function mutation in the ALK2 receptor. In this perspective, we summarize the different
gene therapy options and their expected suitability in FOP
(Table 1).
In general, gene addition aims to introduce genes encoding missing proteins or encoding corrective proteins in
the event that defective proteins are produced by a genetic
mutation. For FOP, where the pathological mutations
cause a gain-of-function, gene therapy could conceivably
apply four strategies, including gene replacement, gene
silencing, combination of gene replacement and silencing,
and gene editing (Table 1). First, introduction of healthy

proteins via gene replacement can be used to compete
against proteins with gain-of-function autosomal dominant mutations such as the classic ALK2 mutation in FOP.
Second, gene silencing aims to suppress the expression of
abnormal proteins at the messenger RNA level by using
ribonucleic acid interference (RNAi). This strategy can
be useful for FOP mutant allele-specific silencing of the
ALK2 receptor.27,28
Third, a combinatory approach of gene replacement
and silencing removes abnormal proteins and expresses
healthy proteins simultaneously. This strategy can be
used to replace the ACVR1 mutation in FOP with normal
ALK2. Finally, gene editing aims to correct DNA mutations in the genome by using the clustered regularly
interspaced short palindromic repeats (CRISPR)/
CRISPR-associated protein 9 (Cas9) system.29,30 This
strategy can be used to correct the ALK2 mutation in
FOP at the genomic levels. However, a caveat to consider in using these therapeutic strategies in FOP is the
lack of definitive identification of the HO-triggering cell
types in the body.
In light of this, the critical question is whether it is
possible to specifically correct the ALK2 mutation in the
cells involved in the various phases of the disease, which
might be a solution, but at the moment still not feasible in
patients. In addition, targeting the locally affected tissue
during a FOP flare-up may also pose difficulties since HO
consists of normal bone tissue (at an ectopic site) which

Table 1. Gene therapy options in fibrodysplasia ossificans progressiva for in vivo treatment

Gene
Gene
Gene
Gene

replacement
silencing
replacement and silencing
editing

Approach

Target

Effect

Expression of wild-type ALK2
Mutant ALK2-specific RNAi
Combination of the two above
CRISPR/CAS-mediated correction of ALK2 mutation

mRNA
mRNA
mRNA
DNA

Normal ALK2 competes against mutant ALK2 receptor
Suppression of mutant ALK2 receptor expression
Combined effect of the two above
Only normal ALK2 receptor is produced

ALK2, activin receptor-like kinase 2; CAS, CRISPR-associated protein; CRISPR, clustered regularly interspaced short palindromic repeats; mRNA, messenger
RNA; RNAi, ribonucleic acid interference.

GENE THERAPY FOR FOP

Figure 3. Two ways to express therapeutic genes in target cells and/or
tissues. (1) Ex vivo gene therapy: genetic modification is executed on isolated patient cells using a viral vector, and after cell expansion in the
culture, treated cells are introduced to patients via infusion. (2) In vivo gene
therapy: AAV vector carrying a therapeutic gene is directly introduced to
patient via systemic or local administration. AAV, adeno-associated virus.

may be difficult to selectively target. These issues may be
circumvented by improving tissue-specific tropism of the
vectors that deliver therapeutic genes.
There are essentially two routes to express therapeutic
genes in target cells and/or tissues (Fig. 3: adapted from
G.G.). Genetically modified cell therapy is an ex vivo treatment approach that extracts target cells from the affected
tissue of the patients, followed by genetic manipulation via
vector-assisted transduction and reintroduction into the tissue.
By contrast, in vivo gene therapy aims for the direct delivery
of therapeutic genes to target tissues using either a viral vector
(i.e., recombinant adeno-associated virus [rAAV] or a nonviral vector [such as liposomes or nanoparticles]).
All FOP cells in the body with the potential to differentiate into bone need to be repaired as any untreated cell
is a potential source of flare-up and HO. Therefore, ex vivo
cell therapy, followed by reintroducing genetically manipulated cells back into the body is unlikely to substantially benefit FOP, because the presence of reintroduced
cells will not affect the cells that contain the mutation.
Consequently, in vivo gene therapy is considered the most
likely treatment option in FOP as presently conceived.

785

Since immunological triggers are known to pose a high
risk for HO induction in FOP, viral vector options need to
be very carefully considered. Each viral vector type has its
advantages and disadvantages in terms of transduction
efficiency, duration of gene expression, transgenic capacity and potential side effects (Table 2).31
Among them, rAAV has a long track record for
safety and efficacy in relevant preclinical and clinical
studies in non-FOP contexts and has been evaluated in
over 130 clinical trials and 2,000 patients worldwide.31,32
AAV, a small (26 nm) nonenveloped parvovirus with a
single-stranded genome of *4.7 kb in length,33 has high
transduction efficiency, persistent transgene expression,
relatively low postinfection immunogenicity, and importantly no association with any human diseases, which
make it an attractive viral vector for use in gene therapy.34
In addition, a systemic disease such as FOP requires a
systemic delivery via the vasculature and takes advantage
of AAV’s transvascularity and tissue-specific tropism.31
However, a high-dose administration of the AAV
vector can potentially trigger an immunomodulatory effect in FOP complicating reliable delivery of the gene of
interest to the target cell(s) and may potentially compromise the subsequent safety of this method as well as any
potential therapeutic effect.35 In addition, flare-ups are
unpredictable and have different phases of development
with involvement of other target cells and their microenvironment. During the HO developmental process, cellular
hypoxia occurs and a periodic diminished blood supply is
suspected, which adds an additional level of complexity in
deciphering the anatomical locations and the target cells
that the vector must be designed to reach.36
Cotreatment with an immunosuppressor or an FOP inhibitor or the development of a new AAV vector that does
not trigger FOP-associated flare-ups may be able to address these issues. Alternatively, liposomes and nanoparticles are nonimmunogenic gene therapy vectors, but
they can be rapidly degraded, cleared in the circulation,
have short biological half-lives, and generally exhibit
nonspecific uptake by cells.34
The CRISPR/Cas9 system has been developed as a
genome-editing tool that can correct DNA mutations un-

Table 2. Comparison of different viral vectors in transduction efficacy, duration of expression, transgenic
capacity, and potential side effects31
AAV

Retrovirus

Lentivirus

Broad host range (infects many cell types)
Infects both dividing and nondividing cells
Genome integration (genotoxicity)

Yes (tissue-specific tropism)
Yes
No

Yes (dividing cells only)
No (dividing cells only)
Yes

Very high level of protein expression
Insert size capacity
Typical titer

No
2.5 kb
1012–1013 GCs/mL

No
2.5–5.0 kb
106 IFU/mL

Yes
Yes
Yes (integrase-deficient
versions available)
No
2.5–5.0 kb
107–108 IFU/mL

AAV, adeno-associated virus; GCs, genome copies; IFU, infectious units.

Adenovirus
Yes
Yes
No
Yes
3.0–8.0 kb
109 IFU/mL
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derlying human diseases. In principle, many heterozygous
mutations can be individually corrected by homologydirected repair (HDR) using an exogenous DNA template.37 Recently, the AAV-compatible Cas9 nuclease
(SaCas9), derived from Staphylococcus aureus, has been
engineered for in vivo gene editing as SaCas9 and fits
within the genome packaging limits of AAV.38 However,
since the SaCas9 nuclease shows a low HDR-mediated
gene-editing efficiency and being a bacterial protein, its
expression triggers immune responses in animal cells.
Consequently, an alternative gene therapy technique
likely needs to be considered, the so-called RNA genetic
techniques.
RNA was conventionally thought to be a transient
messenger (mRNA) for the passive translation of genetic
information encoded by DNA into protein sequences.
However, mRNA comprises only a small fraction of the
RNA types and their functions in the cell. Other types of
RNAs also exist which can turn genes on and off, support
chemical reactions, cut and build other RNAs, and constitute the protein-building machines of cells by transporting and linking amino acids. Taking this into account,
RNA therapies can provide efficient silencing of target
mRNA expression by inhibitory RNA (RNAi) (i.e., siRNA, shRNA, miRNA)-mediated degradation. Similar to
DNA gene therapy, RNAi approaches also require a vector
for delivery into cells, especially since RNA is unstable
and is easily degraded in the bloodstream.
For this reason, RNA therapy can be relatively shortlasting, while high levels of expression can induce cytotoxicity and inflammation by perturbing the RNAi
machinery or leading to significant off-target silencing. To
circumvent these issues, AAV-compatible miRNA scaffolds (artificial miRNA) have been developed to increase
the duration of RNAi expression, limit RNAi-related
toxicity, and enable efficient gene knockdown, while reducing off-target silencing by 10-fold compared to conventional RNAi.31 RNA therapy might theoretically be
preferable in treating flare-ups, although the problem of
not knowing which cell types to target remains.
In summary, after years of setbacks,39 the field of
gene therapy has now achieved some success with effective applications of DNA-modulating therapy in clinical
trials in previously difficult to treat hereditary diseases
such as certain forms of immunodeficiency, neurological disorders, musculoskeletal disorders, blindness, hemoglobinopathies, coagulation disorders, and cancer.31,40
RNA-related gene therapy exists in the form of two
mRNA-based therapies for hereditary transthyretinmediated (ATTR) amyloidosis—a potentially fatal disease
characterized by abnormal protein accumulation in nerves
and organs, including the heart,41 and Nusinersen,42 which
targets a fatal inherited condition called spinal muscular atrophy. Regrettably, the application of Nusinersen is
hampered by high costs. Eteplirsen, a treatment for Du-

chenne muscular dystrophy,43 has been approved by the
Food and Drug Administration (FDA).
One of the biggest barriers44 in the above mentioned
RNA therapies has been the delivery of RNA to the correct
cells. The above mentioned genetic diseases, present relatively accessible affected tissues and cells, which can be
distinctly targeted compared to FOP. Fundamental problems in gene therapy for FOP are the identity of the proper
targets and the safety and durability of the gene targeting
system. An analogy can be made with metastatic cells in
cancer. Any untreated cell is still a potential source of a
flare-up and HO. Since it has recently been shown that
the mutant ALK2 can lead to aberrant gain of BMP signaling in different cell lines and tissue progenitor cells,
with different regeneration capacities,45,46 successful and
comprehensive gene therapy for FOP needs may require
the targeting of broader range of cell types.
Therefore, for a complex disease such as FOP, deeper
insight into the underlying causative cell type(s) and the
factors involved in the different phases of HO is a paramount prerequisite for efficient and safe gene therapy
design. Gene therapy has the clear advantage of achieving
the direct correction of the genetic cause in monogenic
diseases such as FOP, which is lacking in current strategies. This justifies its pursuit as a novel therapeutic modality. While gene therapy could be a promising tool in the
distant future, there are still significant obstacles to overcome until a safe therapy can be offered to the patients.
Considering the complexity of FOP, it can be envisioned that its efficient treatment will involve a combination strategy of gene and pharmacological therapy. As
we learn more about the nature of chronic and traumatic
FOP, it will be possible to evaluate the benefit of vectormediated therapeutic gene and pharmacological treatment
in each for optimal therapeutic outcome. Finally, the discovery of the underlying factors and the natural course of
the disease, in combination with the developing variety of
drug studies and new ongoing options, are all very much
needed to advance FOP treatment and should receive due
attention in the next decade.
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